Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine von Cooper, C.L, Davis, H.L, Morris, M.L, Efler, S.M, Krieg, A.M, Li, Y, Laframboise, C, Al Adhami, M.J, Khaliq, Y, Seguin, I, Cameron, D.W

Volltext

CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study von Cooper, C L, Davis, H L, Morris, M L, Efler, S M, Adhami, M Al, Krieg, A M, Cameron, D W, Heathcote, J

Volltext

Sequence Motifs in Adenoviral DNA Block Immune Activation by Stimulatory CpG Motifs von Krieg, Arthur M., Wu, Tong, Weeratna, Risini, Efler, Susan M., Love-Homan, Laurie, Yang, Lin, Yi, Ae-Kyung, Short, Dan, Davis, Heather L.

Volltext

Designing gene therapy vectors: avoiding immune responses by using tissue-specific promoters von WEERATNA, R. D, WU, T, EFLER, S. M, ZHANG, L, DAVIS, H. L

Volltext

Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response von Siegrist, Claire-Anne, Pihlgren, Maria, Tougne, Chantal, Efler, Sue M., Morris, Mary Lou, AlAdhami, Mohammed J., Cameron, D. William, Cooper, Curtis L., Heathcote, Jenny, Davis, Heather L., Lambert, Paul-Henri

Volltext

Quantification of Oligodeoxynucleotides in Human Plasma with a Novel Hybridization Assay Offers Greatly Enhanced Sensitivity over Capillary Gel Electrophoresis von Efler, S.M., Zhang, L., Noll, B.O., Uhlmann, E., Davis, H.L.

Volltext

CPG 7909, an Immunostimulatory TLR9 Agonist Oligodeoxynucleotide, as Adjuvant to Engerix-B super( registered ) HBV Vaccine in Healthy Adults: A Double-Blind Phase I/II Study von Cooper, Cl, Davis, H L, Morris, M L, EFLER, S M, Adhami, Mal, Krieg, A M, Cameron, D W, Heathcote, J

Volltext

Induction of systemic TH1-Like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleot... von KRIEG, Arthur M, EFLER, Susan M, WITTPOTH, Michael, AL ADHAMI, Mohammed J, DAVIS, Heather L

Volltext

Phase 1B, randomized, double‐blind, dose‐escalation trial of CPG 10101 in patients with chronic hepatitis C virus von McHutchison, John G., Bacon, Bruce R., Gordon, Stuart C., Lawitz, Eric, Shiffman, Mitchell, Afdhal, Nezam H., Jacobson, Ira M., Muir, Andrew, Al‐Adhami, Mohammed, Morris, Mary L., Lekstrom‐Himes, Julie A., Efler, Susan M., Davis, Heather L.

Volltext

Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON™), an investigational synthetic Toll-like receptor 9 agonist von VICARI, Alain P, SCHMALBACH, Tess, LEKSTROM-HIMES, Julie, MORRIS, Mary Louise, AL-ADHAMI, Mohammed J, LAFRAMBOISE, Chantal, LEESE, Philip, KRIEG, Arthur M, EFLER, Susan M, DAVIS, Heather L

Volltext

Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers von Cooper, Curtis L, Ahluwalia, Navneet K, Efler, Susan M, Vollmer, Jörg, Krieg, Arthur M, Davis, Heather L

Volltext

111 Final results of a multi-center phase 1b, randomized, placebo-controlled, doseescalation trial of CPG 10101 in patients with chronic hepatitis C virus von McHutchison, J.G., Bacon, B.R., Gordon, S.C., Lawitz, E., Shiffman, M., Afdhal, N.H., Jacobson, I.M., Muir, A., Vicari, A., Efler, S., Al-Adhami, M., Morris, M.L., Davis, H.L.

Volltext

MFO induction in fish by spent cooking liquors from kraft pulp mills von Hodson, Peter V., Maj, M. K., Efler, S., Burnison, B. K., van Heiningen, A. R. P., Girard, R., Carey, J. H.

Volltext

O.105 Early clinical results with CPG 10101, a new investigational antiviral TRL9 agonist being developed for treatment of subjects chronically infected with hepatitis C virus von McHutchison, J.G., Bacon, B.R., Gordon, S.C., Lawitz, E., Shiffman, M., Afdhal, N.H., Jacobson, I.M., Muir, A., Ghalib, R., Kwo, P., Freilich, B., Davis, H.L., Vicari, A., Efler, S., Al-Adhami, M., Morris, M.L., Masciari, F., Himes, J.L.

Volltext

Early clinical results with CPG 10101, a new investigational antiviral TRL9 agonist being developed for treatment of subjects chronically infected with hepatitis C virus von McHutchison, J G, Bacon, B R, Gordon, S C, Lawitz, E, Shiffman, M, Afdhal, N H, Jacobson, I M, Muir, A, Ghalib, R, Kwo, P, Freilich, B, Davis, H L, Vicari, A, Efler, S, Al-Adhami, M, Morris, M L, Masciari, F, Himes, J L

Volltext

Use of CPG oligonucleotides in the treatment of hepatitis C virus infection von EFLER SUSAN M, DAVIS HEATHER L, VOLLMER JORG, AHLUWALIA NAVNEET K

Volltext bestellen

USE OF CPG OLIGONUCLEOTIDES IN THE TREATMENT OF HEPATITIS C VIRUS INFECTION von SUSAN M. EFLER, NAVNEET K. AHLUWALIA, HEATHER L. DAVIS, JOERG VOLLMER

Volltext bestellen

Anvendelse af CPG-oligonukleotider til behandling af Hepatitis Cvirusinfektion von AHLUWALIA, NAVNEET, K, EFLER, SUSAN, M, VOLLMER, JOERG, DAVIS, HEATHER, L

Volltext bestellen

Use of CPG oligonucleotides in the treatment of hepatitis C virus infection von AHLUWALIA, NAVNEET, K, EFLER, SUSAN, M, VOLLMER, JOERG, DAVIS, HEATHER, L

Volltext bestellen

USE OF CPG OLIGONUCLEOTIDES IN THE TREATMENT OF HEPATITIS C VIRUS INFECTION CPG von AHLUWALIA, NAVNEET, K, EFLER, SUSAN, M, VOLLMER, JOERG, DAVIS, HEATHER, L

Volltext bestellen